Trial Profile
A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Nov 2014
Price :
$35
*
At a glance
- Drugs HIV gp120 vaccine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Genentech
- 01 Nov 2014 New trial record